Hillman Capital Management Inc. Trims Stake in Biogen Inc. $BIIB

Hillman Capital Management Inc. lessened its holdings in Biogen Inc. (NASDAQ:BIIB) by 20.4% during the 4th quarter, HoldingsChannel reports. The firm owned 30,516 shares of the biotechnology company’s stock after selling 7,838 shares during the period. Biogen accounts for approximately 3.4% of Hillman Capital Management Inc.’s portfolio, making the stock its 7th largest position. Hillman Capital Management Inc.’s holdings in Biogen were worth $5,371,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Caprock Group LLC purchased a new position in Biogen during the third quarter worth $742,000. Generali Investments Management Co LLC boosted its stake in Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after buying an additional 8,008 shares during the period. SG Americas Securities LLC boosted its stake in Biogen by 1,793.8% during the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock worth $32,352,000 after buying an additional 174,122 shares during the period. TD Asset Management Inc boosted its stake in Biogen by 12.7% during the third quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock worth $22,580,000 after buying an additional 18,168 shares during the period. Finally, K.J. Harrison & Partners Inc purchased a new position in Biogen during the third quarter worth $1,553,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BIIB has been the subject of several recent analyst reports. Needham & Company LLC raised shares of Biogen from a “hold” rating to a “buy” rating and set a $255.00 price objective for the company in a research note on Monday, June 8th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Rothschild & Co Redburn boosted their target price on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Finally, Piper Sandler reissued an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.70.

Biogen Stock Down 1.5%

Shares of BIIB opened at $195.61 on Wednesday. The firm has a market capitalization of $28.88 billion, a P/E ratio of 20.99 and a beta of 0.20. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The firm has a fifty day moving average price of $189.52 and a 200-day moving average price of $184.58.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.